The majority of AD treatments target neurotransmitter systems; galantamine, rivastigmine, donepezil and tacrine are acetylcholinesterase (AChE) inhibitors, and thus enhance cholinergic transmission. This evidence concerns the gene ACHE and Alzheimer disease.